You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BGB-290

Showing 1 - 25 of 120
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, EGF-R Positive NSCLC Trial in Wuxi (Parimparib, Chemotherapy drug, Targeted Therapy Agent)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • EGF-R Positive Non-Small Cell Lung Cancer
  • Wuxi, Jiangsu, China
    Affiliated Hospital of Jiangnan University
Jan 30, 2023

HER2-negative Breast Cancer Trial in China (BGB-290)

Completed
Has Results
  • HER2-negative Breast Cancer
  • BGB-290
  • Beijing, Beijing, China
  • +21 more
Mar 28, 2022

Ovarian Cancer Trial in China (Pamiparib capsule, Placebo capsule)

Active, not recruiting
  • Ovarian Cancer
  • Pamiparib capsule
  • Placebo capsule
  • Hefei, Anhui, China
  • +27 more
Aug 18, 2022

Metastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Deficiency (HRD) Trial in Worldwide

Terminated
Has Results
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Homologous Recombination Deficiency (HRD)
  • Athens, Georgia
  • +8 more
Oct 20, 2021

Solid Tumors Trial in Worldwide (Tislelizumab, Pamiparib)

Completed
Has Results
  • Solid Tumors
  • Scottsdale, Arizona
  • +28 more
Oct 27, 2021

Limited Stage Small Cell Lung Cancer Trial in Shanghai (Pamiparib)

Recruiting
  • Limited Stage Small Cell Lung Cancer
  • Shanghai, Shanghai, China
  • +1 more
Jul 29, 2022

Clear Cell Papillary Renal Tumor, Collecting Duct Carcinoma, Hereditary Leiomyomatosis and Renal Cell Carcinoma Trial in Los

Recruiting
  • Clear Cell Papillary Renal Neoplasm
  • +10 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Oct 25, 2021

Metastatic Castration-resistant Prostate Cancer Trial in Guangzhou (Pamiparib)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Apr 7, 2022

Advanced High-grade Ovarian Cancer, Triple Negative Breast Cancer Trial in China (Pamiparib)

Active, not recruiting
  • Advanced High-grade Ovarian Cancer
  • Triple Negative Breast Cancer
  • Hefei, Anhui, China
  • +25 more
Jun 16, 2021

For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment Trial in Australia (BGB-290)

Completed
  • For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment
  • BGB-290
  • Hamlyn Terrace, New South Wales, Australia
  • +5 more
Apr 22, 2020

Ovarian Cancer, Carcinosarcoma Trial (Pamiparib)

Withdrawn
  • Ovarian Cancer
  • Carcinosarcoma
  • (no location specified)
Aug 3, 2021

Advanced or Inoperable Gastric Cancer Trial in Worldwide (pamiparib, Placebo)

Completed
  • Advanced or Inoperable Gastric Cancer
  • Santa Rosa, California
  • +140 more
Jan 10, 2023

Advanced Cancer Trial in Worldwide (BGB-A317)

Completed
Has Results
  • Advanced Cancer
  • BGB-A317
  • Boston, Massachusetts
  • +26 more
Oct 18, 2021

Advanced Solid Tumor, Solid Tumor Trial (BGB-26808, Tislelizumab)

Not yet recruiting
  • Advanced Solid Tumor
  • Solid Tumor
  • (no location specified)
Aug 7, 2023

Solid Tumors Trial (BGB-B167, Tislelizumab)

Not yet recruiting
  • Solid Tumors
  • (no location specified)
Dec 1, 2022

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

Solid Tumor Trial in Australia, United States (BGB-B167, Tislelizumab)

Not yet recruiting
  • Solid Tumor
  • Duarte, California
  • +6 more
Aug 8, 2022

Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma Trial (BGB-11417)

Not yet recruiting
  • Mantle Cell Lymphoma
  • +2 more
  • (no location specified)
Jul 25, 2022

Lymphoma, Leukemia Trial in Australia, China (Zanubrutinib, Tislelizumab)

Completed
Has Results
  • Lymphoma
  • Leukemia
  • Darlinghurst, New South Wales, Australia
  • +9 more
Mar 16, 2022

NSCLC Trial (BGB-A445, Docetaxel, Tislelizumab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • (no location specified)
Sep 6, 2023

Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory Trial

Not yet recruiting
  • Waldenstrom Macroglobulinemia
  • +2 more
  • (no location specified)
Jul 18, 2023

Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor Trial in Australia, France, United States (BGB-A3055, Tislelizumab)

Not yet recruiting
  • Advanced Solid Tumor
  • +2 more
  • Iowa City, Iowa
  • +7 more
Jul 5, 2023

Advanced Solid Tumor Trial in Australia, New Zealand, United States (BGB-A445, tislelizumab)

Recruiting
  • Phase 1a:Advanced Solid Tumors; Phase 1b: Non-small Cell Lung Cancer (NSCLC) and Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Pittsburgh, Pennsylvania
  • +11 more
Aug 25, 2022

Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (Ociperlimab, Tislelizumab,

Recruiting
  • Relapsed Diffuse Large B-cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
May 4, 2022

Healthy Volunteers Trial ([14C]-BGB-11417)

Not yet recruiting
  • Healthy Volunteers
  • (no location specified)
Apr 25, 2023